This symposium, presented at ICIEM 2025, provides an overview of sepiapterin as a treatment for phenylketonuria (PKU) and the current PKU disease landscape
All congress activities
International congresses, conferences and meetings offer the opportunity to share data and drive discussion that can progress the management of conditions such as phenylketonuria (PKU). Access our content from recent congresses and society meetings here.
|
Congress
Topic
Type
Year
This symposium, presented at ACMG 2025, summarizes the results from the APHENITY trial, which assessed the effect of sepiapterin on dietary Phe tolerance in a broad population of patients with phenylketonuria (PKU)
This poster, presented at ACMG 2025, describes interim results from the ongoing APHENITY extension study, which evaluated the effect of sepiapterin on dietary Phe tolerance in a broad population of phenylketonuria (PKU) participants
This symposium, presented at SSEIM 2024, provides an overview of sepiapterin as a potential treatment for phenylketonuria (PKU) and its implications for patient management
This symposium, presented at SIMD 2024, discusses the results of the Phase 3 APHENITY trial, which investigated the safety and efficacy of sepiapterin in patients with phenylketonuria (PKU)
This poster, presented at GMDI 2024, describes the APHENITY extension study phenylalanine (Phe) tolerance assessment design and reports on the compliance rate for 3-day diet diaries among participants
This poster, presented at SIMD 2024, discusses the preliminary results from the ongoing APHENITY extension study, which evaluates the safety of sepiapterin and its effect on dietary phenylalanine (Phe) consumption in participants with phenylketonuria (PKU)
This poster, presented at SIMD 2024, evaluates the efficacy and safety data of sepiapterin vs placebo in patients with phenylketonuria (PKU) who were receiving sapropterin dihydrochloride at the time of APHENITY study entry
▼ Sepiapterin is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Adverse events should also be reported to PTC Therapeutics at pharmacovigilance@ptcbio.com.
Registration conditions differ internationally; always consult local prescribing information and/or Summary of Product Characteristics before prescribing any products.
MED-ALL-PTC923-2500012 | September 2025
MED-ALL-PKU-2500224 | October 2025